Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

December 17, 2007

Primary Completion Date

July 23, 2013

Study Completion Date

November 13, 2020

Conditions
Borderline Ovarian Serous TumorLow Grade Ovarian Serous AdenocarcinomaMicropapillary Serous CarcinomaPrimary Peritoneal CarcinomaPrimary Peritoneal Low Grade Serous AdenocarcinomaRecurrent Borderline Ovarian Surface Epithelial-Stromal Tumor
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Selumetinib

Given PO

DRUG

Selumetinib Sulfate

Given PO

Trial Locations (49)

10065

Memorial Sloan Kettering Cancer Center, New York

19001

Abington Memorial Hospital, Abington

19718

Christiana Care Health System-Christiana Hospital, Newark

19958

Beebe Medical Center, Lewes

21921

Christiana Care - Union Hospital, Elkton

27834

Gynecologic Oncology Network, Greenville

28203

Carolinas Medical Center/Levine Cancer Institute, Charlotte

28204

Novant Health Presbyterian Medical Center, Charlotte

39216

University of Mississippi Medical Center, Jackson

43210

Ohio State University Comprehensive Cancer Center, Columbus

43214

Riverside Methodist Hospital, Columbus

43222

Mount Carmel Health Center West, Columbus

44060

UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor

44106

Case Western Reserve University, Cleveland

44109

MetroHealth Medical Center, Cleveland

44111

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland

44124

Hillcrest Hospital Cancer Center, Mayfield Heights

44195

Cleveland Clinic Foundation, Cleveland

45409

Miami Valley Hospital, Dayton

46260

Saint Vincent Hospital and Health Care Center, Indianapolis

49017

Bronson Battle Creek, Battle Creek

49307

Spectrum Health Big Rapids Hospital, Big Rapids

49423

Holland Community Hospital, Holland

49442

Mercy Health Partners-Hackley Campus, Muskegon

49444

Mercy Health Mercy Campus, Muskegon

49503

Cancer Research Consortium of West Michigan NCORP, Grand Rapids

Mercy Health Saint Mary's, Grand Rapids

Spectrum Health at Butterworth Campus, Grand Rapids

49519

Metro Health Hospital, Wyoming

49684

Munson Medical Center, Traverse City

60521

Hinsdale Hematology Oncology Associates Incorporated, Hinsdale

60637

University of Chicago Comprehensive Cancer Center, Chicago

63110

Washington University School of Medicine, St Louis

65804

Cancer Research for the Ozarks NCORP, Springfield

Mercy Hospital Springfield, Springfield

65807

CoxHealth South Hospital, Springfield

73104

University of Oklahoma Health Sciences Center, Oklahoma City

74146

Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa

77030

M D Anderson Cancer Center, Houston

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

94304

Stanford Cancer Institute Palo Alto, Palo Alto

06102

Hartford Hospital, Hartford

06050

The Hospital of Central Connecticut, New Britain

04102

Maine Medical Center-Bramhall Campus, Portland

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Brigham and Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

08103

Cooper Hospital University Medical Center, Camden

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

NRG Oncology

OTHER

lead

National Cancer Institute (NCI)

NIH